Steve,
I don't think my professional background gives me any "great" insight other than the obvious and sensible view, which the company is also touting -- a drug that extends life by a few months for advanced MM, will likely have a huge instant market, and my sense is also that the same market will probably wane over a few years as competitors appear and subsequent outcome studies are done.
JF is a star at Children's Hospital, Boston. He is a simple hard-working persona who's interest in the lab led to a field of study addressing how tumors build blood vessels to themselves, and how therapeutics can be designed to interfere with those processes. I knew him in the 80's so he is an elder-true by now, and to what degree he is still active, and if he is still a peak-producer, I cannot say.
But his name rides very high, as do his connections, in medicine, and so it will remain beyond his physical lifetime.
Still not sure why you thought I might be from the Great White North?
Are you in on this ride up? How high will you hold on for?
Regards, Andrew |
